RTX-240

N/A

Report date: 2022/12/14 20:00:42

Base Information

Drug NameRTX-240

Drug Alias NameRTX-240

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Somatic cell > Erythrocyte therapy

Mechanisms of ActionTumor necrosis factor ligand superfamily member 9 Gene transferenceInterleukin-15 stimulantsInterleukin-15 receptor subunit alpha stimulants

TargetsTumor necrosis factor ligand superfamily member 9Interleukin-15Interleukin-15 receptor subunit alpha

Therapy Area/IndicationsLeukemia, Promyelocytic, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesRubius Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesRubius Therapeutics Inc

Active IndicationsN/A

Inactive IndicationsLeukemia, Promyelocytic, Acute

Other Information

ATC CodeN/A